← Back to Clinical Trials
Recruiting NCT06868771

NCT06868771 Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated with Anti-EGFR

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06868771
Status Recruiting
Phase
Sponsor Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse
Condition Xerosis Cutis
Study Type INTERVENTIONAL
Enrollment 164 participants
Start Date 2022-07-29
Primary Completion 2023-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
topical treatment with the pre- and postbiotic study preparation and niacinamide 4% and one with the 10% urea-based preparation.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 164 participants in total. It began in 2022-07-29 with a primary completion date of 2023-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated With Anti-EGFR.

Eligibility Criteria

Inclusion Criteria: 1. patients aged 18 who have been receiving anti-EGFR therapy for more than three months, 2. signature of the informed consent. Exclusion Criteria: 1. Patients diagnosed with Grade II papulopustulous skin reaction according to the Common Terminology Criteria for Adverse Event (CTCAE) scale at the time of enrolment; 2. concomitant use of emollients and/or steroidal creams; 3. personal history of xerotic pathologies (e.g. lichen, ichthyosis) and/or itching of n.d.d.; 4. inability to provide informed consent or inability to complete the procedures required for enrollment in the study.

Contact & Investigator

Central Contact

Ketty MD Peris

✉ ketty.peris@unicatt.it

📞 0630154211

Principal Investigator

Ketty MD Peris

PRINCIPAL INVESTIGATOR

IRCCS FONDAZIONE POLICLINICO GEMELLI

Frequently Asked Questions

Who can join the NCT06868771 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Xerosis Cutis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06868771 currently recruiting?

Yes, NCT06868771 is actively recruiting participants. Contact the research team at ketty.peris@unicatt.it for enrollment information.

Where is the NCT06868771 trial being conducted?

This trial is being conducted at Roma, Italy.

Who is sponsoring the NCT06868771 clinical trial?

NCT06868771 is sponsored by Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse. The principal investigator is Ketty MD Peris at IRCCS FONDAZIONE POLICLINICO GEMELLI. The trial plans to enroll 164 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology